Real-World Effects and Utilisation Patterns of Elexacaftor, Tezacaftor, and Ivacaftor Combination Therapy (ELX/TEZ/IVA) in Patients with Cystic Fibrosis (CF) First published 15/09/2021 Last updated 03/03/2025 EU PAS number:EUPAS43022 Study Ongoing
Mukoviszidose Institut Germany First published:01/02/2024 Last updated 01/02/2024 Institution Patient organisation/association
European Cystic Fibrosis Society (ECFS) First published:01/02/2024 Last updated 01/02/2024 Institution Educational Institution
Vertex Pharmaceuticals Global Medical Information vertexmedicalinfo@vrtx.comStudy contactvertexmedicalinfo@vrtx.com